New gout drug shows promise in major trial
Disease control
Completed
This study tested a new medicine called AR882 in 818 adults with gout. The goal was to see if it could lower uric acid levels below a target of 6 mg/dL over 6 to 12 months. Participants took either a low dose, a high dose, or a placebo pill. The results will show if AR882 is safe…
Phase: PHASE3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:56 UTC